Cancer Institute of New Jersey (CINJ), Hematologic Malignancies

Medicine & Life Sciences

1. dinaciclib 100%
2. Hodgkin Disease 64%
3. Cyclin-Dependent Kinases 53%
4. Lymphoma 48%
5. Survival 31%
6. Progression-Free Survival 31%
7. Non-Hodgkin's Lymphoma 30%
8. Therapeutics 29%
9. Burkitt Lymphoma 28%
10. Non-Small Cell Lung Carcinoma 26%
11. T-Cell Lymphoma 25%
12. Neoplasms 22%
13. PCI 32765 22%
14. Hereditary Hemorrhagic Telangiectasia 21%
15. Drug Therapy 20%
16. Lymphoma, Large B-Cell, Diffuse 20%
17. Brentuximab Vedotin 18%
18. B-Cell Chronic Lymphocytic Leukemia 15%
19. Immunotherapy 15%
20. Apoptosis 15%
21. abexinostat 15%
22. DNA Sequence Analysis 15%
23. Hematopoietic Stem Cells 14%
24. belinostat 13%
25. Canidae 13%
26. ixazomib 13%
27. Multicenter Studies 13%
28. blinatumomab 13%
29. Pharmacokinetics 12%
30. MK 2206 12%
31. Cyclin-Dependent Kinase 2 12%
32. Chimeric Antigen Receptors 12%
33. Clinical Studies 12%
34. andrographolide 11%
35. Andrographis 11%
36. Aprepitant 11%
37. Transplants 10%
38. Bispecific Antibodies 10%
39. Ipilimumab 10%
40. Cohort Studies 10%
41. Nivolumab 10%
42. Cell- and Tissue-Based Therapy 10%
43. Diterpenes 10%
44. Fatty Acid Synthases 9%
45. Tumor Burden 9%
46. Bevacizumab 9%
47. Lactones 9%
48. Erlotinib Hydrochloride 9%
49. Glutens 9%
50. Hematopoietic Stem Cell Transplantation 9%
51. Cell Line 9%
52. Safety 9%
53. Bortezomib 9%
54. Phosphogluconate Dehydrogenase 9%
55. Malignant Mesothelioma 9%
56. Transitional Cell Carcinoma 8%
57. Heterografts 8%
58. Insurance Coverage 8%
59. Clinical Trials 8%
60. Caspases 8%
61. Stem Cell Transplantation 8%
62. Geriatrics 8%
63. Homologous Transplantation 8%
64. Precursor Cell Lymphoblastic Leukemia-Lymphoma 8%
65. Cone-Beam Computed Tomography 8%
66. Radiosurgery 8%
67. Recurrence 8%
68. Mutation 8%
69. Organ Transplantation 8%
70. Transplantation 8%
71. Graft vs Host Disease 7%
72. Radiotherapy 7%
73. Reactive Oxygen Species 7%
74. Leukemia 7%
75. Central Nervous System 7%
76. Standard of Care 7%
77. Rituximab 7%
78. Tumor Lysis Syndrome 7%
79. Names 7%
80. Pancreatic Neoplasms 7%
81. Natural Killer Cells 6%
82. Human Influenza 6%
83. Survival Rate 6%
84. Hemorrhage 6%
85. Bleomycin 6%
86. Geriatric Assessment 6%
87. T-Lymphocytes 6%
88. Multivariate Analysis 6%
89. Nucleotides 6%
90. Vaccination 6%
91. Urinary Bladder 5%
92. Lung Neoplasms 5%
93. Acute Coronary Syndrome 5%
94. Kinetics 5%
95. Dacarbazine 5%
96. Activities of Daily Living 5%
97. Heart Failure 5%